Skip to main content

Table 1 Patient characteristics (n = 25)

From: Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment

Characteristic Value
Age, years, mean (SD) 60 (11)
Male, n (%) 15 (60)
Race/ethnicity, n (%)
 White 16 (64)
 Hispanic 5 (20)
 Other 4 (16)
Ever smoker, n (%) 12 (48)
Comorbidities, n (%)
 Diabetes mellitus type 2 6 (24)
 Hypertension 18 (72)
 Hyperlipidemia 11 (44)
 Ischemic heart disease 5 (20)
Body mass index, kg/mm2, mean (SD) 28 (5)
Cancer type, n (%)
 Genitourinary cancer 9 (36)
 Hematologic cancer 5 (20)
 Melanoma 4 (16)
 Gastrointestinal cancer 4 (16)
 Other 3 (12)
Cancer stage, n (%)a
 III 4 (16)
 IV 16 (64)
ICI type, n (%)
 Anti–CTLA-4 8 (32)
 Anti–PD-1/L1 15 (60)
 Combination 2 (8)
ICI given with chemotherapy known to cause gallbladder disease, n (%) 4 (16)
Other irAEs, n (%)
 Skin 4 (16)
 Lungs 3 (12)
 Endocrine 3 (12)
 Colitis 1 (4)
 Hepatitis 1 (4)
 Other 2 (8)
  1. aAvailable for 20 patients with solid tumors. SD standard deviation, ICI immune checkpoint inhibitor, CTLA-4 cytotoxic T-lymphocyte associated antigen 4, PD-1/L1 programmed cell death protein 1 or its ligand, irAE immune-related adverse event